Actively Recruiting
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Updated on 2026-01-05
60
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
CONDITIONS
Official Title
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully understand this study and voluntarily sign the informed consent form
- Age 18 years or older at informed consent signing, regardless of gender
- Histologically confirmed relapsed or refractory lymphoma
You will not qualify if you...
- Lymphoma with known central nervous system involvement
- Severe cardiovascular or cerebrovascular diseases
- Any other reason deemed unsuitable for the study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
S
Shuangyu Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here